Individual Dose-escalated Bi-daily Subcutaneously (sc) Ghrelin in Cancer Cachexia: a Phase I/II Study

Advanced Cancer Clinical Trial

Official title:

Individual Dose-escalated Bi-daily sc Ghrelin in Cancer Cachexia: a Phase I/II Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00933361
• Other study ID #: SG 294/08
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: July 6, 2009
• Last updated: July 31, 2017
• Start date: June 2009
• Est. completion date: December 2011

Study information

• Verified date: July 2017
• Source: Cantonal Hospital of St. Gallen
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Cachexia, a condition of severe malnutrition, negative nitrogen balance, muscle wasting, weight loss, and anorexia, is a frequent affecting more than 80% of patients in advanced cancer disease causing a high burden on patients and their families. Nutritional, pharmacological, and behavioural interventions for cancer-related ACS and associated symptoms have, despite the importance for cancer care, limited effect on only a minority of patients. New strategies are required.

Ghrelin, a 28 amino acid peptide discovered in 1999, is predominantly secreted by gastric endocrine cells and is an endogenous ligand for the growth hormone secretagogue (GHS) receptor. When administered peripherally it stimulates growth hormone secretion, food intake, triggers a positive energy balance, produces weight gain through a central mechanism involving hypothalamic neuropeptides and has anti-inflammatory effects. A recently completed trial on intravenous ghrelin in advanced cancer patients with ACS reports good tolerability and safety of single intravenous application of 2 and 8μg/kg Ghrelin.

Given the facts that ACS is a major burden in patients suffering advanced cancer disease and ghrelin is a major signal for stimulating food intake, promoting positive energy balance and weight gain and may have anti-inflammatory effect it remains to be determined whether the administration of ghrelin will have a positive clinical effect on cancer anorexia/ cachexia syndrome ACS. The next logical clinical development step is a proper dose-finding study of twice daily subcutaneous administration and proof-of-concept of main outcomes.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 21
• Est. completion date: December 2011
• Est. primary completion date: December 2011
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion:

• Age: Patients must be older than 18 years of age

• Tumour situation: Patients with any type of advanced (defined as locally recurrent or metastatic), incurable solid tumour.

• Cachexia: defined as involuntary loss of weight of =2% in 2 months or =5% in 6 months, and ongoing in the last 4 weeks

• No simple starvation: Patients must be able to eat, defined as no severe structural barriers in the upper gastrointestinal tract and no bowel obstruction.

• No late cachexia: Patient must have an expected life expectancy > 3 months

• No anti-cachexia or appetite-stimulating medications: Patients are not allowed to have corticosteroids unless for maximum 2 days for chemotherapy, no progestin therapy within the last 2 weeks, no anabolic drugs within the last month. Prokinetic medication, NSAR (paracetamol and novamin sulphate are allowed, if given in a fixed dose for two weeks before visit 1, and expected to be given during the whole trial period.

• Laboratory test results within these ranges: Absolute neutrophil count = 1.5 x 109/L, platelet count = 100 x 109/L, serum creatinine = 2.0 mg/dL (177 µmol/L), creatinine clearance ClCr = 50ml/min, total bilirubin =1.5 mg/dL (25µmol/L), and AST (SGOT)/ ALT (SGPT) =2 x ULN or if hepatic metastases are present = 5 x ULN.

• No other trial: Patient is not or was not participating in any other clinical trial within 28 before visit 2.

• Women of childbearing potential: A negative pregnancy test & effective contraception are mandatory in child-bearing age.

• Men agree not to father a child (i.e. use adequate birth control if sexually active) during participation in the trial.

• Cognition: Presence of a normal level of consciousness (mandatory is a normal abbreviated screening mini-mental test or a common mini-mental = 27/30; in elderly patients age = 65 years or patients with low education a mini mental status of =25/30 points will be considered adequate).

• Consent: The patient has voluntarily signed and dated an independent Ethics Committee (IEC) approved consent prior to any study-specific procedures.

• Gastrectomy: Patients with history of gastrectomy are eligible.

Exclusion:

• Questionnaires: Any psychiatric disorder, alcohol and illicit drug abuser language problem that would prevent the patient from filling in the questionnaires adequately.

• Patient with a history of psychiatric diagnosis of depression or clinical diagnosis of depression as determined by the treating physician or Hospital Anxiety Depression Scale total score of 13 or greater.

• History of alcohol abuse as determined by the CAGE questionnaire (=2/4) or history of illicit drug abuse within last 12 months.

• Parenteral nutrition

• Diabetes mellitus with secondary organ dysfunction: coronary heart disease, previous stroke, renal insufficiency

• Patients with cerebral metastases or prophylactic whole brain irradiation for possible cerebral metastases.

• Known hypersensitivity to ghrelin.

• Known infection with HIV or a viral hepatitis

• Patients with known myeloid malignancy or tumours having bone marrow involvement

• Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.

• Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.

Related Conditions & MeSH terms

• Advanced Cancer
• Cachexia

Intervention

Drug:
• ghrelin
As starting dose the investigators choose a dose level which was shown in our last study to be safe in human beings, i.e. 8µg/kg intravenously. With an assumed bioavailability of 25% of subcutaneously administered ghrelin the corresponding dose for dose level 1 is therefore 32 µg/kg. In the first 4 dose levels for each subsequent dose level the dose is increased by 50% compared to the previous one, from the 5th dose level onwards the increase is 25%: Dose level 1 = 32 µg/kg Dose level 2 = 48 µg/kg Dose level 3 = 72 µg/kg Dose level 4 = 108 µg/kg Dose level 5 = 135 µg/kg Dose level 6 = 169 µg/kg Dose level 7 = 211 µg/kg The investigators define the maximum tolerable dose as 20mg ghrelin (equivalent to 5ml) for reasons of the high drug volume to be administered subcutaneously.

Locations

Country	Name	City	State
Switzerland	Cantonal Hospital St. Gallen KSSG	St. Gallen

Sponsors (2)

Lead Sponsor	Collaborator
Cantonal Hospital of St. Gallen	Bachem

Country where clinical trial is conducted

Switzerland, 

References & Publications (1)

Strasser F, Lutz TA, Maeder MT, Thuerlimann B, Bueche D, Tschöp M, Kaufmann K, Holst B, Brändle M, von Moos R, Demmer R, Cerny T. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. Br J Cancer. 2008 Jan 29;98(2):300-8. doi: 10.1038/sj.bjc.6604148. Epub 2008 Jan 8. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To assess the dose of ghrelin in tumour patients with ACS causing optimal stimulation of nutritional intake - minimal dose for maximal nutritional intake (MD-MANI) - or the maximally tolerable dose (MTD), which one occurs first		bi-weekly
Primary	To assess the effect of ghrelin on muscle strength.		weekly
Secondary	To assess the toxicity and tolerability, pharmacokinetics and symptoms of eating of ghrelin.		bi-weekly
Secondary	To assess the effect of ghrelin on muscle mass, physical function, safety, toxicity and tolerability, pharmacokinetics, symptoms of eating, gastrointestinal motility, inflammation		weekly